Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHAT | P28329 | 2/20 | 0.40 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.39 |
| ▸ | DPYD | Q12882 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690157 | 1.00 | NFE2L2 (0.54) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL14690155 | 1.00 | NFE2L2 (0.54) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL27805506 | 0.92 | NFE2L2 (0.47) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| Methane SCHEMBL27583285 | 0.90 | NFE2L2 (0.46) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL14690304 | 0.90 | NQO2 (0.47) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL14690301 | 0.90 | NQO2 (0.47) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL14690303 | 0.90 | NQO2 (0.47) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL10622271 | 0.86 | CHAT (0.47) | NFE2L2TRPA1CHAT | |
| SCHEMBL13932212 | 0.83 | NFE2L2 (0.50) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 | |
| SCHEMBL27830937 | 0.81 | NFE2L2 (0.48) | NFE2L2TRPA1MAOBSIGMAR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2741731-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2741731-A1 | ENCAPSULATES | The Procter and Gamble Company (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2013022949-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | NFE2L2 3370/4885TRPA1 942/4885MAOB 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.